Lianhuaqingwen (LHQW) is a compounded Chinese herbal medicine that is produced by addition and reduction of combined Yinqiao powders and
Maxing Shigan decoction,
which has multiple therapeutic targets and comprehensive therapeutic action . Mo et al.  gave LHQW capsules to patients with human influenza A virus infection for
different time periods and found that it affects various parts of or inhibits human influenza A virus infection through several mechanisms, including prevention of virus adsorption,
inhibition of replication and proliferation after viral adsorption, and having a direct antivirus effect. The experimental studies performed by China Academy of Traditional
Chinese Medicine showed a definite antibacterial action of LHQW, which could disrupt bacterial biofilms, significantly inhibit the number of viable cells at the intramembrane,
and have bacterial resistance properties. The Pharmacology of Traditional Chinese Medicine, Hebei Medical University, found that LHQW had inhibiting effects on
Staphylococcus aureus, alpha- and beta
hemolytic Streptococcus, pneumococcus, Haemophilus, and influenza. Li  analyzed 136
cases with influenza complicated
with bronchial pneumonia and found that patients who received LHQW capsules had more symptom improvement than did those in the control group.
These findings indicated that LHQW was effective for concurrent viral and bacterial infections. Guo et al. 
investigated the influenza virus infection of blood T lymphocyte subsets in mice and found that LHQW had regulatory functions on cellular immunity.
The above studies suggested that LHQW can be used to treat AECOPD due to its anti-infective and immunomodulatory effects. In animal experiments, our research
group  found that LHQW capsules could clearly reduce the levels of IL-8 and TNF- in serum, lung tissue, and bronchial lavage fluid of COPD rats (), and we confirmed
its ability to suppress airway inflammation in COPD.